Compared with matched healthy tissue, PXDN is up-regulated in a number of different cancers (Table 1 and Figure 2) including melanoma [19–21], sarcoma [22], glioblastoma [22–24], oral carcinoma [25,26], prostate and testicular cancer [22,27], ovarian cancer [22,28], pancreatic cancer [22,29], thyroid cancer [30], head and neck cancer [22] and stomach cancer [22]. Here, PXDN is linked to ovarian carcinoma.